Scalper1 News
Goldman Sachs upgraded Eli Lilly (LLY) to neutral Thursday, saying the big pharma had “turned the corner” after falling hard off the patent cliff. But the investment bank downgraded Johnson & Johnson, citing increasing drug competition. “We believe LLY has turned the corner with improving margins and new product launches driving the company out of its earnings trough and the next five years setting up well for double-digit EPS growth,” analyst Scalper1 News
Scalper1 News